SLC5A2 and Hyperglycemia: When this is insufficient for managing the hyperglycemia, GLP-1 receptor agonists or SGLT2 inhibitors are suggested for subjects with established atherosclerotic cardiovascular disease and when there is a compelling need to prevent weight gain.